Latest From XenoPort Inc.
This latest roundup includes EFPIA's appointment of Nathalie Moll to director general, CEO appointments by YposKesi and Symbiomix Therapeutics, as well as various executive appointments by PureTech Health, Arterial Capital Management and Mitra Biotech.
FDA can improve drug pricing by limiting the number of orphan designations, AHIP argues; worryingly for industry, the agency appears to be already thinking along similar lines.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2016.
Ireland's Jazz pays $1.5bn to acquire Celator and its hotly anticipated leukemia drug, Vyxeos; Spero takes over antibacterial program out-licensed by Vertex; Novartis to copromote Eisai's Lenvima.
- Controlled Release
- Drug Delivery
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- XenoPort Inc.
- Senior Management
William G Harris, SVP, Fin. & CFO
Richard K Kim, MD, SVP, Clin. Dev. & Med. Affairs & CMO
- Contact Info
Phone: (408) 616-7200
3410 Central Expressway
Santa Clara, CA 95051
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.